Wilmington, Del. - 14 April 2015 - Incyte Corporation will establish the new headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.
“Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer,” said Hervé Hoppenot, President and CEO of Incyte Corporation.
“We are confident that Incyte will benefit from the international talent pool in Geneva and the surrounding region, and that the company’s presence will further enhance Geneva’s standing as an important hub in the biotechnology industry,” said Mr. Pierre Maudet, Minister of the Department of Security and Economy for the Republic and Canton of Geneva.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.